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Abstract
Background: Juvenile idiopathic arthritis (JIA) is an inflammatory arthritis of unknown etiology, which lasts for
greater than 6 weeks with onset before 16 years of age. JIA is the most common chronic rheumatic disease in
children. NSAIDs have been the mainstay of initial management with naproxen (NAP) being commonly used, but
they may cause serious side effects such as gastric ulcers which can be reduced by concomitant administration of
proton pump inhibitors, such as esomeprazole (ESO).
Methods: Primary objective was to evaluate the safety and tolerability of 3 fixed doses of NAP/ESO in JIA patients
aged 12 to 16 years. Forty-six children and adolescents with JIA by International League of Associations for
Rheumatology criteria, mean age of 13.6 years, from 18 US sites were prospectively enrolled over 2 years and followed
for up to 6 months. Doses of the NAP/ESO fixed combination were based on baseline weight. The exploratory efficacy
outcome was assessed with the ACR Pediatric-30, − 50, − 70, − 90 Response and the Childhood Health Assessment
Questionnaire (CHAQ) discomfort and functional scores at months 1, 3, and 6 as change from baseline. Occurrence and
causality were assessed for treatment emergent AEs (TEAEs) and discontinuations were monitored monthly.
Results: Forty-six patients received at least 1 dose of naproxen/esomeprazole and 36 completed the trial. Thirty-seven
(80.4%) had at least 1 treatment emergent adverse event (TEAE) and, with the exception of 2 events in one patient, all of
the TEAEs were mild or moderate. Frequent TEAEs (≥5% of patients) were upper respiratory tract and gastrointestinal
related. Eleven (23.9%) had at least 1 TEAE considered to be related to study drug. Four patients (8.7%) discontinued due
to a TEAE with one of these being the only serious AE reported, acute hepatitis. Mean number of active joints at baseline
was 3.1. Improvement in JIA signs and symptoms occurred at most assessments and by month 6, the percentage of
patients with an ACR Pediatric-30, − 50, − 70, and − 90 Response was 47.1, 38.2, 32.4, and 17.6%, respectively. The percent
of patients achieving ACR Pediatric response increased over time. CHAQ discomfort improved at each assessment and
functional scores improved at all assessments for ‘Arising, Walking, and Activities’ with several improved for ‘Dressing and
Grooming, Eating, Hygiene, and Grip’. There was no indication of a dose-related efficacy effect.
(Continued on next page)
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Conclusion: NAP/ESO was well tolerated in JIA patients aged 12 to 16 years with high levels of response to ACR criteria.
No new safety signals were identified for the well-characterized components of this fixed dosed JIA treatment, which was
developed to reduce the risk of gastric ulcers.
Trial registration: Clinicaltrials.gov, NCT01544114. Registered February 21, 2012.
Keywords: Juvenile idiopathic arthritis, Non-steroidal anti-inflammatory drugs (NSAIDs), Naproxen, Esomeprazole
Background
Juvenile idiopathic arthritis (JIA) is an inflammatory arth-
ritis of unknown etiology, which lasts for greater than
6 weeks with onset before 16 years of age [1, 2]. Per the
American College of Rheumatology (ACR) guidelines, JIA
is the most common chronic rheumatic disease in children
[3]. Non-steroidal anti-inflammatory drugs (NSAIDs) have
been the mainstay of initial management with naproxen be-
ing frequently prescribed, but they can cause serious side
effects such as gastric ulcers. The ACR recommends
NSAIDs and/or intra-articular steroids as first line therapy
for oligoarticular JIA and as supplemental to other primary
therapies [3, 4]. Monotherapy has been suggested to be suc-
cessful in children less than 8 years of age, with low levels
of disease burden [5]. However, children of all ages gener-
ally tolerate NSAIDs better than adults, but naproxen’s use
in JIA is associated with gastrointestinal (GI) events in over
36% of patients, which can be a limiting factor for its use
[6, 7]. Naproxen is approved by the Food and Drug Admin-
istration (FDA) for pediatric patients ≥2 years of age with
JIA in dosages not greater than 15 mg/kg/day.
For pediatric patients up to 17 years of age, a
delayed-release form of esomeprazole magnesium is ap-
proved in many countries for the short-term treatment
(8 weeks) of gastroesophageal reflux disease and has been
shown to be safe and effective [8]. An immediate-release
(IR) form of esomeprazole magnesium was developed to
allow for sequential gastric release of esomeprazole just
prior to that of naproxen to provide maximum gastropro-
tective effects. A fixed combination product of this IR
esomeprazole magnesium and naproxen was then devel-
oped and approved for use in adults with rheumatoid arth-
ritis, osteoarthritis, and ankylosing spondylitis, and in
adolescents with JIA, to reduce the incidence of NSAID
related gastric ulcers. Herein, we report the first results of a
JIA clinical efficacy and safety trial of three different doses
of a combination product of naproxen with 20 mg of IR
esomeprazole.
Methods
Study design
The study was a phase 4, US only, multicenter, open-label,
single arm, non-comparator study (Fig. 1) designed to
evaluate the safety of 250 mg, 375 mg, or 500 mg of na-
proxen combined with 20 mg of esomeprazole in a fixed
combination (NAP/ESO) given twice a day (BID) 30 min
prior to the morning and evening meals for up to
6 months.
Adolescent male and female patients, age 12 to 16 years
(inclusive), with an established diagnosis of JIA as defined
by the International League of Associations for Rheuma-
tology criteria were eligible for enrollment [1]. Patients
who turned 17 years of age during the study were allowed
to continue in the study. Enrollment of a sufficient num-
ber of patients to obtain 45 evaluable patients at approxi-
mately 20 study sites was planned, with evaluable patients
defined as those who took at least 1 dose of study drug.
The Screening period was up to 30 days, and the Treat-
ment period with open-label NAP/ESO was up to
6 months with a 2-week follow-up period for assessment
of safety, for a total of ‘in study’ time of 7.5 months. Pa-
tients were screened for eligibility during Visit 1 (Screen-
ing visit) after the signed informed consent and assent
were obtained. Medical history and prior/concomitant
medication history were obtained, a complete physical
examination (blood pressure [BP], pulse rate, oral
temperature, height and weight), 12-lead electrocardio-
gram (ECG), eye exams, and blood and urine samples for
determination of clinical chemistry (including serum iron/
total iron binding capacity, vitamin B12 and magnesium),
hematology and urinalysis were collected at Screening.
Screening (Visit 1) and entry into the Treatment period
(Visit 2, Day 1) could have occurred during the same visit if
the site performed all study Visit 1 and Visit 2 procedures
within the same day, and if laboratory results were available
to assess a patient’s eligibility during that visit. Patients were
dispensed study drug only after all Visit 1 and Visit 2
procedures were performed and eligibility was con-
firmed. Patients returned to the study site for sched-
uled visits at the end of Months 1, 3, and 6
(±7 days), and were contacted via scheduled tele-
phone calls at Months 2, 4, and 5 (±7 days). After
the end of the Treatment period, safety was assessed
by telephone after a 2-week follow-up period.
Safety assessments (adverse events [AEs], serious AEs
[SAEs], concomitant medications, physical examinations
with vital signs, weight, clinical chemistry and hematology)
were performed at each scheduled visit. Ophthalmologic
examinations were performed in accordance with the
American Academy of Pediatrics guidelines [9]. AEs, SAEs,
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and concomitant medications were also assessed during
telephone calls. Efficacy assessments were collected at base-
line and at Months 1, 3, and 6. Blood samples for naproxen
and esomeprazole PK analysis were collected for frequent
sampling (Month 1, up to 8 patients) or sparse sampling
(Months 1 and 3, remaining patients).
Study drug was dispensed at the start of the Treatment
period and at Months 1 and 3, and unused study drug
was collected at Months 1, 3, and 6. The NAP/ESO
strength for each patient was determined by the patient’s
weight at baseline (Table 1) and the Investigator’s discre-
tion according to clinical guidelines on naproxen’s use
[10]. The same dose assigned at baseline was maintained
throughout the study. The naproxen and esomeprazole
dosages are consistent with the previously identified safe
and effective weight/age-appropriate doses administered
to adolescent patients [8, 10, 11]. Study drug compliance
was monitored at each visit by tablet counts from the
returned bottles. Total tablets taken were defined as the
difference of the returned from the total number dis-
pensed. Any patient taking less than 80% or more than
120% of the assigned study drug was considered
non-compliant.
Main inclusion criteria (full criteria provided in
supplement)
1. Patients were male or female adolescents age 12 to
16 years at the time of enrollment.
2. Patient was diagnosed with JIA, including all the
ILAR JIA subtypes: oligoarthritis, polyarthritis (both
RF+ and RF-), psoriatic arthritis, enthesitis-related
arthritis, undifferentiated arthritis, and systemic
arthritis (those with presence of fever, rheumatoid
rash, serositis, lymphadenopathy, macrophage acti-
vation syndrome in the past 6 months were
excluded).
3. Patients who do not require ad hoc use of either
active ingredient (naproxen or esomeprazole)
4. Patient’s body weight was > 31 kg and within the
5th to 95th percentile of body mass index (BMI)
for age.
Main exclusion criteria (full criteria listed in supplement)
1. Received treatment with any investigational agent
12 weeks or 5 half-lives of the investigational drug
(whichever was longer) prior to Visit 2.
2. Had systemic JIA with presence of fever,
rheumatoid rash, serositis, lymphadenopathy,
macrophage activation syndrome within 6 months
prior to start of study treatment.
3. Were receiving current treatment (i.e., within
4 weeks prior to start of study treatment) with
Fig. 1 Overview of Study Design. Visits 1 and 2 could have been combined if results from all assessments at Visit 1 were obtained at the time of
Visit 1. If Visits 1 and 2 were conducted on the same day, visit procedures that were specific to Visit 2 were also conducted during Visit 1. The
telephone call during the 2-week safety follow-up period was required for all patients (i.e., patients who completed the full 6 months of
treatment, patients who completed less than 6 months of treatment, patients who discontinued early from the study, and patients who took at
least 1 dose of study drug)
Table 1 Minimum and Maximum Study Drug Dose (naproxen/
esomeprazole magnesium) by Weight Group
Weight at Enrollment (kg)a Minimum Doseb Maximum Doseb
< 38 250 mg / 20 mg 250 mg / 20 mg
38 - < 50 250 mg / 20 mg 375 mg / 20 mg
50 - < 75 375 mg / 20 mg 500 mg / 20 mg
≥75 500 mg / 20 mg 500 mg / 20 mg
aBased on typial day-to-day fluctuations in body weight, a ± 3% window for
body weight was permitted and used at the discretion of the Investigator
when assigning the initial dose group
bStudy drug (naproxen/esomeprazole magnesium) dose, twice daily (BID)
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naproxen > 20 mg/kg/day or > 1000 mg total daily
dose.
4. Had any significant unstable hepatic, renal,
pulmonary, ophthalmologic, neurologic or any
other medical conditions indicated by medical/
surgical history, physical or laboratory examination
which would have confounded the study or put the
patient at risk.
5. Had uncontrolled hypertension [12].
Prior and Concomitant Therapy
Use of the following drugs was allowed during the study:
– Concomitant JIA medications, including anti-
tumor necrosis factors, as long as the dosing
regimen was stable for 1 month prior to
enrollment.
– Acetaminophen and glucocorticoid intra-articular
injections on an as needed basis.
– Corticosteroids, limited to ≤10 mg or 0.2 mg/kg
prednisone equivalent per day (whichever was less).
– Methotrexate treatment ≤25 mg/week or 15 mg/m2/
week (whichever was less).
Use of the following drugs was prohibited during the
study:
– Treatment with another NSAID including additional
naproxen at enrollment and during the study.
NSAIDs, other than the study drug were prohibited
during the study.
– Continuous treatment with antacids, H2-receptor
antagonists, or proton pump inhibitor (PPI), in
addition to the NAP/ESO received during this study.
– Continuous treatment with antifungals,
antiretroviral drugs (atazanavir, nelfinavir,
saquinavir), cilostazol, or warfarin (Coumadin®) or
the use of these agents at any time between Visit 1
(Screening visit) and the final study visit (Visit 8 or
ET visit). Concomitant use of the listed drugs is not
recommended with esomeprazole.
Other medications, including over-the-counter medi-
cations and non-prescription dietary supplements that
were considered necessary for the patient’s safety and
well-being, were permitted at the discretion of the Inves-
tigator. Patients who were on prohibited medications
could participate in the study if they discontinued their
medication within 24 h of Visit 2, if deemed medically
appropriate. In addition to the prohibited/restricted
medications, addition of new treatment, treatment dis-
continuation, and change of dosage/administration was
to be avoided as much as possible.
Primary study endpoints
The primary objective was to evaluate the safety and tol-
erability of NAP/ESO in adolescents aged 12 to 16 years
inclusive, with JIA, including the incidence and severity
of adverse events (AEs) and serious AEs (SAEs), a
change from baseline in vital signs, physical examination
results and clinical laboratory results as well as serum
iron/TIBC, vitamin B12 and magnesium levels.
Drug discontinuations were monitored monthly.
Secondary objective
The pharmacokinetic (PK) characteristics of NAP/ESO
in adolescents aged 12 to 16 years, inclusive, with JIA
were evaluated and compared to historically reported
adult and pediatric PK data of the individual compo-
nents. Overall exposure was calculated for esomeprazole
and exposure to naproxen was described by an analysis
of trough levels, since naproxen is slowly absorbed and
excreted over time. PK parameters were compared with
that published previously for adult and pediatric
patients.
Exploratory efficacy objective
Disease activity was assessed with the ACR Pediatric re-
sponse scores derived from the following:
– Physician’s global assessment of disease activity
during the last 24 h prior to a visit was recorded
using a 21-numbered circle visual analog scale
(VAS) in 0.5 increments anchored by 0 = “no activ-
ity” and 10 = “maximum activity.” The change from
baseline and percentage change from baseline was
calculated at each scheduled post-baseline visit.
– CHAQ global assessment of well-being was rated for
each patient by their parent at each scheduled visit
using a 21-numbered VAS in 0.5 unit increments
anchored by 0 = “very well” and 10 = “very poor”
[13].
– CHAQ disability index score was calculated at each
scheduled visit based on a 4-point Likert scale of 0 =
“without any difficulty,” 1 = “with some difficulty,” 2
= “with much difficulty,” and 3 = “unable to do” as
the mean of the non-missing functional area scores.
If more than 2 of the 8 functional area scores were
missing, then the disability index score was consid-
ered missing (i.e., a minimum of 6 functional area
scores had to be non-missing).
– Number of joints with active arthritis was recorded.
A joint was considered to have active arthritis if the
patient had any of the following for the joint:
– Swelling, and/or
– Loss of motion and pain on motion, and/or
– Loss of motion and tenderness
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Right and left joints were considered separately (e.g.,
both right and left wrists could have had active arthritis
and would be counted as 2 joints with active arthritis).
– Number of joints with limited range of motion was
recorded. A joint was considered to have limited
range of motion if the patient has any of the
following for that joint:
– Loss of motion and pain on motion, and/or
– Loss of motion and tenderness.
Right and left joints were considered separately (e.g.,
both right and left wrists could have had limited range
of motion and would be counted as 2 joints with limited
range of motion).
-Either serum C-reactive protein (CRP) or erythrocyte
sedimentation rate (ESR). The test done at baseline was
to have been continued at post-baseline visits, to assess
change from baseline.
CHAQ discomfort index was also rated for each pa-
tient by their parent at each scheduled visit using a
21-numbered VAS in 0.5 unit increments anchored by 0
= “no pain” to 10 = “very severe pain.”
CHAQ Functional area scores. Eight functional areas
were assessed (dressing and grooming, arising, eating,
walking, hygiene, reach, grip, and activities) on a Likert
scale of 1 to 4. For analysis purposes, responses were
recoded using a scoring system of 0 = “without any diffi-
culty,” 1 = “with some difficulty,” 2 = “with much diffi-
culty” and 3 = “unable to do” to be consistent with the
CHAQ scoring defined by Singh et al. [14].
Analyses
As this was an open-label study, no hypothesis testing
was performed. All safety and efficacy endpoints were
summarized by descriptive statistics. For categorical vari-
ables, counts and percentages were presented. For con-
tinuous variables, the following were presented: n, mean,
median, standard deviation, minimum, and maximum.
Change from baseline values were calculated as the visit
value minus the baseline value. Negative mean numbers
of the individual changes indicated an improvement
from baseline.
For the PK analysis, summary statistics of trough na-
proxen plasma concentration (lowest plasma concentra-
tion from pre-dose to 3 h post-dose) during steady state
were presented by dose group and visit. Empirical Bayes’
estimates of the individual PK parameters were gener-
ated based on the final structural and variance param-
eter estimates and the individual plasma concentration
measurements using nonlinear mixed effects modeling
(NONMEM). Esomeprazole PK parameter estimates de-
rived from this Population (Pop) PK analysis were ana-
lyzed and listed by study dose group and individual
patient. The geometric %CV was calculated as
100 × √[exp(s2)-1], where s was the standard deviation of
the data on a natural log scale.
Results
Disposition and demographics
Fifty-one patients were enrolled at 18 US sites over
2 years. Forty-six patients were assigned treatment.
Forty-four patients received at least 1 dose of study drug
and had at least 1 post-baseline assessment of any of the
study parameters. Thirty-six (78.3%) of the treated pa-
tients received 6 months of study drug (defined as
≥166 days on study drug). Mean drug exposure was
5.5 months. See patient disposition in Table 2. Mean
age, weight, and number of active joints at baseline were
13.6 years, 55.2 kg and 3.1, respectively (Table 3).
Five patients received glucocorticoids for JIA or “arth-
ritis” related reasons during the study. Three patients re-
ceived a total of 4 steroid joint injections. Two of the
patients receiving injections also received low dose (≤
10 mg) oral prednisone (one for only one day and the
other on numerous days), 1 received oral prednisone
from 5 to 80 mg on multiple days, and 1 received
7.5 mg oral prednisone on one day. Of the concomitant
disease modifying agents of interest, 26 (56.5%) patients
were on 1 or more of the following immunomodulators:
methotrexate, adalimumab, infliximab, tocilizumab, aba-
tacept, etanercept, leflunomide, rituximab, sulfasalazine,
hydroxychloroquine sulfate. During the study, 11 pa-
tients either started new, switched immunomodulators
or had their dose changed.
Primary outcomes
 Thirty-seven patients (80.4%) had at least 1 TEAE
(Table 4), as defined by the Medical Dictionary for
Regulatory Activities (MedDRA). Frequent TEAEs
(≥5%) were upper respiratory tract infection, upper
abdominal pain, sinusitis, diarrhea, headache,
nausea, and ligament sprain. Four patients (8.7%)
discontinued due to a TEAE (1 SAE of hepatitis and
3 non-serious events; 1 patient with numbness, 1 pa-
tient with abdominal pain/dyspepsia, and 1 patient
with worsening of JIA).
 All of the TEAEs were mild or moderate, with the
exception of a 13 year old female, who had a SAE of
acute hepatitis and a severe non-serious event of ab-
normal liver function tests. The patient had a history
of hepatic steatosis (by liver biopsy), abdominal dis-
comfort, parotitis, and jaw pain. Notably, the patient
was not on concomitant methotrexate or other im-
munomodulators. On Day 22 of study drug treat-
ment, the patient experienced dramatically increased
AST and ALT compared to baseline. On Day 85,
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serologic testing was non-reactive for hepatitis A, B,
and C. Study drug was permanently discontinued on
Day 88 and the patient was withdrawn from the
study. After withdrawal, the patient was hospitalized
for a liver biopsy, which showed mixed inflammatory
changes involving both hepatocytes and bile ducts in
portal triads. A diagnosis of acute hepatitis with a
possible etiology of drug induced or biliary cirrhosis
was given. Patient was further treated in hospital
and recovered. Both events were considered resolved
on Day 157, with the hepatitis considered reasonably
related to the study drug. Gastrointestinal AEs were
reported in 17 patients, most frequently upper ab-
dominal pain, diarrhea and nausea. (Table 4). There
were no severe or serious GI events. Of these 17 pa-
tients, 7 were on concomitant disease modifying
agents (methotrexate, infliximab, leflunomide and
tocilizumab).
 A total of 11 (23.9%) patients had at least 1
TEAE considered by the Investigator to be
related to the study drug and 3 discontinued due
to TEAE considered to be related to the study
drug (hepatitis, numbness, and abdominal pain/
dyspepsia).
 The only study drug-related TEAE that occurred
in ≥5% of all patients was upper abdominal pain
(3 [6.5%] patients).
 Due to a theoretical risk of decreased levels for iron,
vitamin B12, and magnesium during long-term PPI
exposure, potential alterations in these moieties dur-
ing 6 months of PPI therapy were evaluated and no
significant changes were seen.
Secondary outcomes- pharmacokinetics
Forty patients supplied samples for esomeprazole and 41
provided samples for naproxen. Esomeprazole concen-
trations observed in adolescents are comparable to those
previously reported in adult and adolescent studies [15].
Geometric mean values of esomeprazole CL/F and V/F
were higher in this pediatric study compared to the esti-
mates in adult (CL/F: 24.66 vs. 12.79 L/h/70kg0.75; V/F:
38.68 vs. 21.03 L/70 kg). Individual oral CL/F estimates
in adolescent subjects (ranging from 3.84 to 131.91 L/h/
70kg0.75) were within the range of estimates observed in
adults (3.43–136.62 L/h/70kg0.75) [15]. Total esomepra-
zole exposures (estimated as AUCs) ranged from 0.51 to
19.69 μmol·h/L in adolescent subjects and from 0.46 to
14.68 μmol·h/L in adult healthy volunteers, and are
comparable to previously reported values in the litera-
ture [8, 15–17]. Naproxen Cmax and Tmax data in fre-
quently sampled pediatric patients were comparable to
those reported in pediatric studies [18, 19] and adult
studies [20]. Naproxen concentrations in terms of range
and variability in this study were comparable to what
was previously reported in children [18]. See supplemen-
tal materials for summary of naproxen and esomeprazole
plasma concentration frequent and sparse sampling
groups (Additional file 1: Tables S1 and S2).
Efficacy assessment
 The percentage of patients achieving ACR Pediatric
response increased over time (Fig. 2).
 The mean baseline score for physician’s assessment
of disease activity was 2.58 and individual mean
Table 2 Patient Disposition
Number (%) of Patients
Naproxen/Esomeprazole
Magnesium
250 mg/20 mg
Naproxen/Esomeprazole
Magnesium
375 mg/20 mg
Naproxen/Esomeprazole
Magnesium
500 mg/20 mg
Total
Enrolled 51
Not assigned treatment (eligibility criteria
not fulfilled)
5
Assigned treatment 4 20 22 46
-Received study drug 4 (100) 20 (100) 22 (100) 46
(100)
-Completed study and received 6 mo of
study drug
3 (75.0) 16 (80.0) 17 (77.3) 36
(78.3)
-Discontinued prematurely 1 (25.0) 4 (20.0) 5 (22.7) 10
(21.7)
-Adverse event 1 (25.0) 1 (5.0) 2 (9.1) 4 (8.7)
-Lost to follow-up 0 2 (10.0) 0 2 (4.3)
-Severe non-compliance with protocol 0 1 (5.0) 0 1 (2.2)
-Withdrew consent 0 0 3 (13.6) 3 (6.5)
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improvement from baseline was − 0.67, − 0.99, and
− 1.23 at Months 1, 3, and 6, respectively.
 Mean CHAQ global assessment of Well-Being base-
line score was 3.43 and mean improvement from
baseline was − 0.80, − 0.93, and − 1.39 at Months 1,
3, and 6.
 Mean CHAQ functional scores indicated
improvement from baseline for 3 of the functional
Table 3 Demographics and Baseline Characteristics
Naproxen/Esomeprazole
Magnesium
250 mg/20 mg
(N = 4)
Naproxen/Esomeprazole
Magnesium
375 mg/20 mg
(N = 20)
Naproxen/Esomeprazole
Magnesium
500 mg/20 mg
(N = 22)
Total
(N = 46)
Age (years)
Mean 12.8 13.6 13.8 13.6
SD 0.96 1.47 1.33 1.37
Median 12.5 13.0 13.5 13.0
Min, Max 12, 14 12, 16 12, 16 12, 16
Sex, n (%)
Female 3 (75.0) 15 (75.0) 15 (68.2) 33 (71.7)
Male 1 (25.0) 5 (25.0) 7 (31.8) 13 (28.3)
Race, n (%)
White 4 (100) 15 (75.0) 17 (77.3) 36 (78.3)
Black or African
American
0 3 (15.0) 2 (9.1) 5 (10.9)
Asian 0 0 2 (9.1) 2 (4.3)
Other 0 2 (10.0) 1 (4.5) 3 (6.5)
Weight (kg)
Mean 39.3 53.8 59.4 55.2
SD 2.63 9.37 8.27 10.07
Median 38.5 50.5 58.0 54.5
Min, Max 37, 43 42, 76 49, 76 37, 76
Height (cm)
Mean 157.5 158.6 162.5 160.4
SD 4.73 8.78 7.70 8.14
Median 156.0 156.5 159.5 158.5
Min, Max 154, 164 144, 175 152, 176 144, 176
BMI (kg/m2)
Mean 15.86 21.34 22.56 21.45
SD 1.579 2.797 3.476 3.534
Median 15.41 20.42 21.69 20.75
Min, Max 14.5, 18.1 16.8, 26.6 17.3, 32.0 14.5,
32.0
No. of Joints With Active Arthritisa
N 4 19 21 44
Mean 1.0 4.1 2.5 3.1
SD 1.15 10.56 3.84 7.39
Median 1.0 1.0 1.0 1.0
Min, Max 0, 2 0, 46 0, 16 0, 46
BMI body mass index, max maximum, min minimum, SD standard deviation
aA joint was considered to have active arthritis if the patient had any of the following: swelling, loss of motion and pain on motion, and/or loss of motion and
tenderness. Right and left joints were considered separately (e.g., both right and left wrists could have had active arthritis and would have been counted as 2
joints with active arthritis)
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areas (arising, walking, and activities). For 4 of the
functional areas (dressing and grooming, eating,
hygiene, and grip), the mean change from baseline
indicated an improvement or no change (mean
change 0.0) at each assessment. For the remaining
functional area of ‘reach’, there was no change at
each post-baseline assessment except Month 1
(mean change 0.2).
 The mean baseline score for the CHAQ disability
index was 0.506. The mean improvement from
baseline was − 0.069, − 0.064, and − 0.155 at Months
1, 3, and 6, respectively.
 The mean baseline number of joints with active
arthritis was 3.1. The individual mean change
indicated an improvement from baseline to each
post-baseline assessment. The mean improvement
from baseline was − 1.1, − 0.4, and − 0.6 at Months
1, 3, and 6, respectively.
 The mean baseline number of joints with limited
range of motion was 1.7. The individual mean
improvement from baseline was − 0.9, − 0.1, and −
0.2 at Months 1, 3, and 6, respectively.
 The mean baseline serum CRP was 8.807 mg/mL
with a mean change of 0.169, − 1.076, and − 1.120 at
Months 1, 3, and 6, respectively, indicating
individual mean improvement at Months 3 and 6.
 The mean baseline serum ESR was 10.4 mm/hr. The
mean individual change indicated improvement
Table 4 TEAEs occurring in at least 2 patients
Number (%) of Patients
MedDRA System Organ Class
Preferred Term
NAP/ESO
250 mg/20 mg
(N = 4)
NAP/ESO
375 mg/20 mg
(N = 20)
NAP/ESO
500 mg/20 mg
(N = 22)
Total
(N = 46)
Patient with any TEAE 4 (100) 16 (80.0) 17 (77.3) 37 (80.4)
Gastrointestinal disorders 1 (25.0) 8 (40.0) 8 (36.4) 17 (37.0)
Abdominal pain upper 0 3 (15.0) 2 (9.1) 5 (10.9)
Diarrhea 0 2 (10.0 2 (9.1) 4 (8.7)
Nausea 0 3 (15.0) 1 (4.5) 4 (8.7)
Abdominal discomfort 0 2 (10.0) 0 2 (4.3)
Dyspepsia 0 0 2 (9.1) 2 (4.3)
Vomiting 0 1 (5.0) 1 (4.5) 2 (4.3)
Infections and infestations 2 (50.0) 4 (20.0) 9 (40.9) 15 (32.6)
Upper respiratory tract infection 1 (25.0) 2 (10.0) 6 (27.3) 9 (19.6)
Sinusitis 0 1 (5.0) 4 (18.2) 5 (10.9)
Gastroenteritis viral 0 0 2 (9.1) 2 (4.3)
Tooth infection 0 1 (5.0) 1 (4.5) 2 (4.3)
Musculoskeletal and connective tissue disorders 2 (50.0) 2 (10.0) 2 (9.1) 6 (13.0)
Back pain 1 (25.0) 1 (5.0) 0 2 (4.3)
Pain in extremity 0 1 (5.0) 1 (4.5) 2 (4.3)
Injury, poisoning and procedural complications 0 2 (10.0) 3 (13.6) 5 (10.9)
Ligament sprain 0 0 3 (13.6) 3 (6.5)
Nervous system disorders 2 (50.0) 1 (5.0) 2 (9.1) 5 (10.9)
Headache 1 (25.0) 1 (5.0) 2 (9.1) 4 (8.7)
General disorders and administration site conditions 0 0 2 (9.1) 2 (4.3)
Fatigue 0 0 2 (9.1) 2 (4.3)
Immune system disorders 0 1 (5.0) 1 (4.5) 2 (4.3)
Hypersensitivity 0 1 (5.0) 1 (4.5) 2 (4.3)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps) 1 (25.0) 1 (5.0) 0 2 (4.3)
Skin papilloma 1 (25.0) 1 (5.0) 0 2 (4.3)
Respiratory, thoracic and mediastinal disorders 0 1 (5.0) 1 (4.5) 2 (4.3)
Cough 0 1 (5.0) 1 (4.5) 2 (4.3)
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from baseline to Month 3. The mean change from
baseline was 0.4, − 0.1, and 0.8 at Months 1, 3, and
6, respectively.
 CHAQ discomfort improved at each assessment
from a baseline mean of 4.41. The mean
improvement from baseline was − 1.24, − 1.21, and
− 2.20 at Months 1, 3, and 6.
 There was no indication of a dose-related efficacy ef-
fect in any of the outcomes.
 Adherence with study medication was good with
73.9% of patients (34 of 46) with ≥80% and ≤ 120%
compliance and 21.7% (10 of 46 patients)
demonstrating < 80% or > 120% (non-compliance).
Two subjects were lost to follow-up and therefore
did not have an overall compliance calculated.
Additional analyses
Twenty-six of the 46 patients who were assigned treat-
ment with NAP/ESO were also taking a DMARD/bio-
logic during the study and the remaining patients
utilized NAP/ESO as their primary therapy. Those who
were on co-therapy and had variables to determine a
month 6 ACR response (N = 21) displayed a greater in-
crease in percentage of patients with ACR Response 30,
− 50, − 70, and − 90 when compared to those using
NAP/ESO as their primary therapy (Fig. 3). Baseline
demographics of the co-therapy group appeared similar
to the primary therapy group (see Additional file 1:
Table S3), and baseline disease measures showed a trend
of increased severity in the co-therapy group (see Add-
itional file 1: Table S4).
Discussion
The fixed combination of naproxen and esomeprazole
was well tolerated in this population of 12 to 16-year-old
patients with JIA, and no new safety signals were
Fig. 2 ACR Scores. The number above each bar represents the number of patients at that dose. The four patients in the lowest dose group did
not reach any ACR response at Month 1. The ACR Pediatric-30, −50, −70, and − 90 responses were defined as an improvement of at least 30% (or
50, 70, 90%, respectively) from baseline in at least 3 of the 6 signs and symptoms variables, with no more than 1 of the remaining variables
worsening by > 30%. JIA signs and symptoms variables: physician’s global assessment of disease activity, CHAQ disability index score, CHAQ
global assessment of well-being, number of joints with active arthritis, number of joints with limited range of motion, serum CRP or ESR
Fig. 3 ACR Response in patients with co-therapy and in patients
with NSAID as primary therapy at month 6
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identified. The safety results were consistent with the
well-characterized profiles of the components; naproxen
and esomeprazole magnesium.
Esomeprazole was selected as the PPI of choice for
this combination because of its well-documented
acid-inhibiting properties [21] and its proven efficacy in
reducing the risk of NSAID-associated gastric ulcers
[22]. Naproxen was chosen because historically, up to
85% of JIA patients have been treated with NSAIDs [23],
with naproxen noted to be the predominate NSAID in
use recently [5]. In a previous trial, naproxen was noted
to produce GI AEs in 39.6% of patients with the event
rate driven predominantly by abdominal pain in an ado-
lescent patient population aged 12–17, similar to this
study. The abdominal pain rate found in this study was
10.9% [24]. Research should continue on identifying
which JIA patients will benefit the most from NSAID
therapy as well as those most at risk for NSAID induced
GI events who would benefit from gastroprotection with
this fixed combination of naproxen and esomeprazole.
Our study found good results with naproxen/esome-
prazole monotherapy with ACR 30 and 50 responses in
31% of our JIA patients. However, our data seem to indi-
cate that patients with higher disease activity respond
better to combination immunomodulator therapy and
naproxen/esomeprazole, as evidenced by higher ACR 30
and 50 responses, though none of the baseline differ-
ences were statistically significantly different between
the two groups.
At baseline, patients in this study were on mean ap-
proximately 14 years of age, had 3 active joints, and a
CRP of about 9. Our patients demonstrated good re-
sponses over the observation period with 47% achieving
an ACR-30, 38% receiving an ACR-50, 32% receiving an
ACR-70 response, and 18% receiving an ACR-90 re-
sponse at month 6. Improvements were observed in JIA
signs and symptoms, the CHAQ discomfort index, and
several CHAQ functional area scores. The percentage of
patients that achieved an ACR Pediatric response in-
creased over time during the study and were generally
similar to historic NSAID study results indicating signifi-
cant responses between 25 to 33% of patients [25].
There was no association of the weight based doses
with response indicating that the doses chosen in this
study were appropriate and in line with published guide-
lines [10]. We did not, however, titrate doses to deter-
mine optimal efficacy, but the doses used in this study
(mean of ≈ 15.5 mg/kg/day) represent previously identi-
fied effective doses of naproxen for JIA treatment, with a
target range of between 10 and 20 mg/kg/day divided
twice daily with a maximum of 1000 mg/day. Only 4 pa-
tients received the lowest dose (250 mg NAP/20 mg
ESO), and therefore there was limited data within the
lowest weight group, leading to the currently
recommended FDA approval of the fixed dosage form in
those patients 12 years of age and older weighing at least
38 kg, requiring naproxen for symptomatic relief of arth-
ritis and esomeprazole magnesium to decrease the risk
of developing naproxen-associated gastric ulcers [26].
Mean drug exposure was approximately 165 days in
the 46 patients, with 36 (78.3%) of them receiving
6 months of study drug (defined as ≥166 days on study
drug). The PK results approximated the esomeprazole
PK data from previously published pediatric studies. The
naproxen Cmax and Tmax values in the more frequently
sampled pediatric patients were comparable to those re-
ported in the literature [18–20]. In addition, naproxen
concentrations in terms of range and variability in this
pediatric study were comparable to that previously re-
ported in children. These results indicated that combin-
ing esomeprazole and naproxen did not result in any
significant interaction affecting overall pharmacokinetics
of the individual components of the fixed dosage form.
Conclusions
The fixed combination of NAP/ESO was well tolerated
in JIA patients aged 12 to 16 years. No new safety signals
were identified for the well-characterized components of
this fixed dosed JIA treatment, which was developed to
reduce the risk of gastric ulcers in patients requiring
chronic naproxen therapy. Improvement in JIA signs
and symptoms occurred at most assessments and by
month 6, the percentage of patients with an ACR
Pediatric-30, − 50, − 70, and − 90 Response was 47.1,
38.2, 32.4, and 17.6%, respectively.
Additional file
Additional file 1: Supplemental Data. (DOCX 54 kb)
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